AEZS News Alert Aeterna Zentaris (AEZS) 0.59 12/25/2014 02:5

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeterna Zentaris (AEZS) 0.59 $AEZS

Biotech Weekly: A Few Rules And Regulations Affecting Biotech Investors
Daniel Ward - Seeking Alpha - Mon Dec 22, 11:57AM CST
The biotech sector continued its amazing year this week with both the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB ) and the SPDR S&P Biotech ETF (NYSEARCA: XBI ) closing the week up 3.6%. The popular IBB is now up 39.7% just this year while the...
NERV: 5.63 (+0.15), XBI: 182.62 (+3.44), DARA: 0.87 (+0.05), AEZS: 0.59 (-0.02)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Aeterna Zentaris, Inc. and Certain Officers - AEZS
PR Newswire - Fri Dec 19, 4:06PM CST
Pomerantz LLP has filed a class action lawsuit against Aeterna Zentaris, Inc. ("Aeterna" or the "Company" (NASDAQ: AEZS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased Aeterna securities between June 26, 2012 and November 5, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
AEZS: 0.59 (-0.02)

Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price
PR Newswire - Fri Dec 19, 8:00AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company" announced today that it has received a notice from The NASDAQ Listing Qualifications Department indicating that the Company's minimum bid price has fallen below $1.00 for 30 consecutive business days, and, therefore, was no longer in compliance with NASDAQ Marketplace Rule 5550(a)(2) - bid price. The Company has been provided 180 calendar days, or until June 16, 2015, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days. This notice does not impact the Company's listing on The NASDAQ Capital Market at this time.
AEZ.TO: 0.68 (-0.01), AEZS: 0.59 (-0.02)

Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris
PR Newswire - Wed Dec 17, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Novavax Inc. (NASDAQ: NVAX), Amarin Corporation PLC (NASDAQ: AMRN), Immunomedics Inc. (NASDAQ: IMMU), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 16, 2014, the NASDAQ Composite ended at 4,547.83, down 1.24%, the Dow Jones Industrial Average declined 0.65%, to finish the day at 17,068.87, and the S&P 500 closed at 1,972.74, down 0.85%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 776.88, down 1.27%, while the index has advanced 4.39% in the previous three months. Register for your complimentary reports on these five stocks at:
IMMU: 4.41 (+0.13), NVAX: 5.81 (+0.18), AMRN: 0.99 (unch), AEZS: 0.59 (-0.02), CELG: 109.60 (+3.48), CELGZ: 3.34 (-0.01)

INVESTOR ALERT: Class Action Lawsuit Against Aeterna Zentaris Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Dec 16, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of purchasers of the securities of Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ:AEZS) between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" . Aeterna is a specialty biopharmaceutical company, and is developing macimorelin a^' an orally active small molecule that stimulates the secretion of growth hormone a^' as a treatment for Adult Growth Hormone Deficiency.
AEZS: 0.59 (-0.02)

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015 -- AEZS
GlobeNewswire - Thu Dec 11, 3:10PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq:AEZS) securities between October 18, 2012 and November 5, 2014.
AEZS: 0.59 (-0.02)

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Aeterna Zentaris Inc.
Business Wire - Thu Dec 11, 12:42PM CST
Glancy Binkow & Goldberg LLP reminds investors of Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ:AEZS) that purchasers of Aeterna securities between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" , have until January 12, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of New Jersey.
AEZS: 0.59 (-0.02)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aeterna Zentaris, Inc. to Contact Brower Piven Before the January 12, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- AEZS
GlobeNewswire - Tue Dec 09, 9:10PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq:AEZS) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff.
AEZS: 0.59 (-0.02)

Update: My Discussion With RedChip And Thoughts Going Forward
Daniel Ward - at Seeking Alpha - Mon Dec 08, 8:08AM CST

XBI: 182.62 (+3.44), AKER: 3.20 (-0.10), AEZS: 0.59 (-0.02)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Aeterna Zentaris, Inc. of Class Action Lawsuit and Upcoming Deadline -- AEZS
GlobeNewswire - Fri Dec 05, 1:40PM CST
Pomerantz LLP has filed a class action lawsuit against Aeterna Zentaris, Inc. ("Aeterna" or the "Company" (Nasdaq:AEZS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased Aeterna securities between June 26, 2012 and November 5, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
AEZS: 0.59 (-0.02)

Cancer Cachexia - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/nngtcd/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Eli Lilly and Company - Novartis - Aphios - GTx - Incyte - AEterna Zentaris - Helsinn Healthcare - Radius Health - Vicus Therapeutics - Ohr Pharmaceutical - KAEL-GemVax - RaQualia Pharma - Acacia Pharma - PsiOxus Therapeutics - Signablok - Myomics For more information visit http://www.researchandmarkets.com/research/nn...r_cachexia
RDUS: 37.17 (+0.11), AMGN: 160.67 (+3.15), AEZS: 0.59 (-0.02), OHRP: 8.54 (+0.14), LLY: 70.16 (+0.42), NVS: 93.91 (+0.66)

Aeterna Zentaris adds to up move
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 12:05PM CST

AEZS: 0.59 (-0.02)

Stock to Watch: AEterna Zentaris Up 16.9% (AEZS)
Comtex SmarTrend(R) - Mon Dec 01, 11:36AM CST
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 16.9% to $0.61 on 1.1x average daily volume. AEterna Zentaris has traded 2.9 million shares thus far today, vs. average volume of 2.8 million shares per day. The stock has outperformed the Dow (16.9% to the Dow's -0.3%) and outperformed the S&P 500 (16.9% to the S&P's -0.7%) during today's trading.
AEZS: 0.59 (-0.02)

Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin Doxorubicin in China
PR Newswire - Mon Dec 01, 6:30AM CST
All amounts are in U.S. dollars
AEZ.TO: 0.68 (-0.01), AEZS: 0.59 (-0.02)

EQUITY ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc. Investors of Important Deadline in Class Action Filed by the Firm -- AEZS
GlobeNewswire - Fri Nov 28, 5:45PM CST
Rosen Law Firm reminds purchasers of Aeterna Zentaris, Inc. securities (Nasdaq:AEZS) between October 18, 2012 and November 6, 2014 of the important January 12, 2015 lead plaintiff deadline in the class action filed by the firm.
AEZS: 0.59 (-0.02)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Aeterna Zentaris, Inc. To Contact Brower Piven Before The January 12, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Nov 25, 5:15PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq: AEZS) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff.
AEZS: 0.59 (-0.02)

Robbins Arroyo LLP: Aeterna Zentaris Inc. (AEZS) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Tue Nov 25, 5:04PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Aeterna Zentaris Inc. (Nasdaq:AEZS) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between October 18, 2012 and November 5, 2014. Aeterna Zentaris is a specialty biopharmaceutical company that develops and commercializes novel treatments in oncology and endocrinology.
AEZS: 0.59 (-0.02)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Aeterna Zentaris Inc. (AEZS) to Contact the Firm
Marketwired - Fri Nov 21, 7:20PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, notifies investors of the class action lawsuit filed against Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ: AEZS) in the United States District Court for the District of New Jersey.
AEZS: 0.59 (-0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 81

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Join Flywire Corporation Securities Class Action

Updated Category News Views 219

Investors Urged to Join Flywire Corporation Securities Class Action The recent developments surrounding Flywire Corporation (NASDAQ: FLYW) have captured the attention of investors, especially those who purchased securities during the specified period. The Rosen Law Firm, known for championing investor rights, is taking the lead in facilitating a securities fraud lawsuit...

Continue Reading
Unicycive Therapeutics Faces Investigation Over Stock Concerns

Updated Category News Views 231

Unicycive Therapeutics Under Investigation for Securities Fraud In recent developments, Pomerantz LLP has initiated an investigation into the possible fraudulent activities involving Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The inquiry focuses on whether the company and its executives may have violated securities laws, an issue that could have implications for many...

Continue Reading
Investors Urged to Act: Join Wolfspeed's Upcoming Class Action

Updated Category News Views 313

Overview of Wolfspeed's Class Action Wolfspeed, Inc. investors are encouraged to take action regarding their stakes in the company as a class action lawsuit surfaces. The Rosen Law Firm, a reputable entity specializing in investor rights, sets a significant deadline for participation in this case. It’s essential for anyone who purchased shares within the specified...

Continue Reading
Pacsun Champions Co-Creation at Music's Grandest Stage

Updated Category News Views 194

Pacsun Champions Co-Creation at Music's Grandest Stage Youth Retailer Debuts Co-Branded Merchandise and Artist Performances As Grammy Weekend celebrates the top talents in music, Pacsun embraces the opportunity to highlight the emerging artists and professionals shaping the future of music. Their approach emphasizes co-creation, access, and cultural participation, crucial...

Continue Reading
Vistra Corp Enhances Financial Stability with Credit Facility Boost

Updated Category News Views 134

Vistra Corp Strengthens Financial Flexibility In a strategic move to enhance its financial flexibility, Vistra Corp. (NYSE:VST), known for delivering electric services, has taken steps to amend its credit agreement. The changes not only extend the maturity date of its credit facility but also expand its borrowing capabilities. This adjustment, effective October 2, 2024,...

Continue Reading